Literature DB >> 22818100

No need to abandon unilateral parathyroid surgery.

Richard Hodin, Peter Angelos, Sally Carty, Herb Chen, Orlo Clark, Gerard Doherty, Quan-Yang Duh, Douglas B Evans, Keith Heller, William Inabnet, Electron Kebebew, Janice Pasieka, Nancy Perrier, Cord Sturgeon.   

Abstract

Mesh：

Year:  2012        PMID： 22818100     DOI： 10.1016/j.jamcollsurg.2012.04.024

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN： 1072-7515            Impact factor:   6.113


× No keyword cloud information.
  5 in total

1.  Minimally invasive parathyroid surgery.

Authors:  Randall P Owen; Carl E Silver; Ashok R Shaha; Phillip K Pellitteri; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-01-31       Impact factor: 2.503

2.  The small abnormal parathyroid gland is increasingly common and heralds operative complexity.

Authors:  Kelly L McCoy; Naomi H Chen; Michaele J Armstrong; Gina M Howell; Michael T Stang; Linwah Yip; Sally E Carty
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

3.  Justified follow-up: a final intraoperative parathyroid hormone (ioPTH) Over 40 pg/mL is associated with an increased risk of persistence and recurrence in primary hyperparathyroidism.

Authors:  Mohammad H Rajaei; Alex M Bentz; David F Schneider; Rebecca S Sippel; Herbert Chen; Sarah C Oltmann
Journal:  Ann Surg Oncol       Date:  2014-09-06       Impact factor: 5.344

4.  Surgical Management of Primary Hyperparathyroidism in the Era of Focused Parathyroidectomy: A Study in Tertiary Referral Centre of North India.

Authors:  Sanjay K Yadav; Saroj K Mishra; Anjali Mishra; Sabaretnam Mayilvagnan; Gyan Chand; Gaurav Agarwal; Amit Agarwal; Ashok K Verma
Journal:  Indian J Endocrinol Metab       Date:  2019 Jul-Aug

Review 5.  A Review of Parathyroid Surgery for Primary Hyperparathyroidism from the United Kingdom Registry of Endocrine and Thyroid Surgery (UKRETS).

Authors:  H Ishii; M J Stechman; J C Watkinson; S Aspinall; D S Kim
Journal:  World J Surg       Date:  2020-12-02       Impact factor: 3.352
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.